Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Sapropterin

Nature Reviews Drug Discovery volume 7, pages 199–200 (2008)Cite this article

Abstract

Sapropterin dihydrochloride (Kuvan; BioMarin) is a synthetic form of tetrahydrobiopterin, the natural cofactor for the enzyme phenylalanine hydroxylase (PAH). In December 2007, it became the first drug to be approved by the US FDA for the treatment of phenylketonuria, a genetic disorder that is characterized by PAH deficiency.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Scriver, C. R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 28, 831–845 (2007).

    Article  CAS  Google Scholar 

  2. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16–18, 2000. Pediatrics 108, 972–982 (2001).

  3. Blau, N. & Erlandsen, H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 82, 101–111 (2004).

    Article  CAS  Google Scholar 

  4. Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375–378 (1999).

    Article  CAS  Google Scholar 

  5. Muntau, A. C. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 347, 2122–2132 (2002).

    Article  CAS  Google Scholar 

  6. Food and Drug Administration. FDA labelling information [online], (2007).

  7. Burton, B. K. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a Phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 30, 700–707 (2007).

    Article  CAS  Google Scholar 

  8. Levy, H. L. et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a Phase III randomised placebo-controlled study. Lancet 370, 504–510 (2007).

    Article  CAS  Google Scholar 

  9. Waisbren, S. E. et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 92, 63–70 (2007).

    Article  CAS  Google Scholar 

  10. IMS, MIDAS Quantum (September 2007).

Download references

Author information

Author notes

  1. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. skar@uk.imshealth.com

  2. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com

Authors and Affiliations

  1. Barbara K. Burton is at the Department of Pediatrics, Children's Memorial Hospital, Northwestern University, Feinberg School of Medicine, 2300 Children's Plaza, Box 59, Chicago, Illinois 60614, USA. BBurton@childrensmemorial.org,

    Barbara K. Burton, Santwana Kar & Peter Kirkpatrick

Authors
  1. Barbara K. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Barbara K. Burton has received research funding from BioMarin for clinical trials in PKU involving sapropterin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burton, B., Kar, S. & Kirkpatrick, P. Sapropterin. Nat Rev Drug Discov 7, 199–200 (2008). https://doi.org/10.1038/nrd2540

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2540

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing